Aravive Dividends and Buybacks

Dividend criteria checks 0/6

Aravive does not have a record of paying a dividend.

Key information

n/a

Dividend yield

-1,358.5%

Buyback Yield

Total Shareholder Yield-1,358.5%
Future Dividend Yieldn/a
Dividend Growthn/a
Next dividend pay daten/a
Ex dividend daten/a
Dividend per sharen/a
Payout ration/a

Recent dividend and buyback updates

No updates

Recent updates

Here's Why Aravive (NASDAQ:ARAV) Must Use Its Cash Wisely

Apr 26
Here's Why Aravive (NASDAQ:ARAV) Must Use Its Cash Wisely

Here's Why Aravive (NASDAQ:ARAV) Must Use Its Cash Wisely

Sep 03
Here's Why Aravive (NASDAQ:ARAV) Must Use Its Cash Wisely

Aravive Q2 GAAP EPS misses, revenue beats

Aug 11

Aravive appoints Robert Geller as CMO

Jul 05

We Think Aravive (NASDAQ:ARAV) Needs To Drive Business Growth Carefully

May 15
We Think Aravive (NASDAQ:ARAV) Needs To Drive Business Growth Carefully

Companies Like Aravive (NASDAQ:ARAV) Are In A Position To Invest In Growth

Nov 06
Companies Like Aravive (NASDAQ:ARAV) Are In A Position To Invest In Growth

Companies Like Aravive (NASDAQ:ARAV) Are In A Position To Invest In Growth

Jun 25
Companies Like Aravive (NASDAQ:ARAV) Are In A Position To Invest In Growth

Aravive EPS beats by $0.01, misses on revenue

May 06

Aravive shares rise after dosing first patient in late-stage ovarian cancer study

Apr 27

Did Business Growth Power Aravive's (NASDAQ:ARAV) Share Price Gain of 121%?

Mar 18
Did Business Growth Power Aravive's (NASDAQ:ARAV) Share Price Gain of 121%?

Companies Like Aravive (NASDAQ:ARAV) Are In A Position To Invest In Growth

Feb 09
Companies Like Aravive (NASDAQ:ARAV) Are In A Position To Invest In Growth

Aravive: Pipeline-In-A-Pill In Oncology

Dec 28

Aravive (ARAV) Investor Presentation - Slideshow

Dec 04

Aravive late-stage study of AVB-500 in platinum-resistant ovarian cancer part of FDA's innovative trial design initiative

Nov 19

Aravive, 3D Medicine inks licensing pact for AVB-500 for Greater China

Nov 10

Stability and Growth of Payments

Fetching dividends data

Stable Dividend: Insufficient data to determine if ARAV's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ARAV's dividend payments have been increasing.


Dividend Yield vs Market

Aravive Dividend Yield vs Market
How does ARAV dividend yield compare to the market?
SegmentDividend Yield
Company (ARAV)n/a
Market Bottom 25% (US)1.4%
Market Top 25% (US)4.4%
Industry Average (Biotechs)2.4%
Analyst forecast (ARAV) (up to 3 years)n/a

Notable Dividend: Unable to evaluate ARAV's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate ARAV's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate ARAV's payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as ARAV has not reported any payouts.


Discover strong dividend paying companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/01/29 07:24
End of Day Share Price 2024/01/29 00:00
Earnings2023/09/30
Annual Earnings2022/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Aravive, Inc. is covered by 16 analysts. of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
null nullBTIG
John NewmanCanaccord Genuity
Louise ChenCantor Fitzgerald & Co.